[
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly",
    "summary": "The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since then, the company has been dealing with litigation, trying its best to get away with it without having to pay much. The progress on the lawsuit is likely to be decided in […]",
    "url": "https://finnhub.io/api/news?id=766346311ae2b37d161e930f035f32fe0666b714dbacc717fb1f09b22a1c22bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731080322,
      "headline": "Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly",
      "id": 131236815,
      "image": "https://s.yimg.com/ny/api/res/1.2/P9YwnFZE7kMqIed.JxKATQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/737851002d1165d613f66ae8979f5cb4",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since then, the company has been dealing with litigation, trying its best to get away with it without having to pay much. The progress on the lawsuit is likely to be decided in […]",
      "url": "https://finnhub.io/api/news?id=766346311ae2b37d161e930f035f32fe0666b714dbacc717fb1f09b22a1c22bc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in the U.S. and DARZALEX® subcutaneous (SC) formulation in the European Union (EU). The applications are supported by data from the ongoing Phase 3 AQUILA study (NCT03301220) of DARZALEX FASPRO® as monotherapy for the treatment of adul",
    "url": "https://finnhub.io/api/news?id=700200ca0455aee883a0d0262dc31cd42cefd407367db86e0f70c443ccd51884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731067200,
      "headline": "Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma",
      "id": 131236817,
      "image": "https://media.zenfs.com/en/prnewswire.com/a55456a3d9715ae208e774a7b73fad68",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in the U.S. and DARZALEX® subcutaneous (SC) formulation in the European Union (EU). The applications are supported by data from the ongoing Phase 3 AQUILA study (NCT03301220) of DARZALEX FASPRO® as monotherapy for the treatment of adul",
      "url": "https://finnhub.io/api/news?id=700200ca0455aee883a0d0262dc31cd42cefd407367db86e0f70c443ccd51884"
    }
  },
  {
    "ts": null,
    "headline": "J&J: FDA & EMA applications for Darzalex Faspro in myeloma",
    "summary": "Johnson & Johnson announces that it has submitted applications to the FDA and EMA for a new indication for Darzalex Faspro in the United States and for the subcutaneous formulation Darzalex in the...",
    "url": "https://finnhub.io/api/news?id=c788edf715ebf4c826a62672d2705ab3b94ae9e3c88afd9e0d98d91d67e5ea0b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731062172,
      "headline": "J&J: FDA & EMA applications for Darzalex Faspro in myeloma",
      "id": 131219289,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that it has submitted applications to the FDA and EMA for a new indication for Darzalex Faspro in the United States and for the subcutaneous formulation Darzalex in the...",
      "url": "https://finnhub.io/api/news?id=c788edf715ebf4c826a62672d2705ab3b94ae9e3c88afd9e0d98d91d67e5ea0b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib",
    "summary": "The platform works in conjunction with the CARTO 3 system, enhancing the safety of ablation procedures.",
    "url": "https://finnhub.io/api/news?id=4f18a0209ec6a4329c86ce41ac40a548cee3ce1e98700e68b0b843d2c4b356de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731061663,
      "headline": "Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib",
      "id": 131236819,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/11/AF-shutterstock_1806320335.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The platform works in conjunction with the CARTO 3 system, enhancing the safety of ablation procedures.",
      "url": "https://finnhub.io/api/news?id=4f18a0209ec6a4329c86ce41ac40a548cee3ce1e98700e68b0b843d2c4b356de"
    }
  },
  {
    "ts": null,
    "headline": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
    "summary": "You'll also like these stocks for their track record of earnings growth.",
    "url": "https://finnhub.io/api/news?id=e4cc3fbe1c09dbbccb21bcbd63080d5d57565411e7cf4e81d202cff9e776bc41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731057300,
      "headline": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
      "id": 131201603,
      "image": "https://g.foolcdn.com/editorial/images/796743/gettyimages-smiling-investor.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "You'll also like these stocks for their track record of earnings growth.",
      "url": "https://finnhub.io/api/news?id=e4cc3fbe1c09dbbccb21bcbd63080d5d57565411e7cf4e81d202cff9e776bc41"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson advances leadership in rheumatic disease innovation With 43 abstracts at ACR 2024",
    "summary": "SPRING HOUSE - Johnson & Johnson announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology 2024...",
    "url": "https://finnhub.io/api/news?id=a093b1cd9c3d78ac452d743a7ef305fb962dfd4c54f17bc67398c69d7da25b2d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731048387,
      "headline": "Johnson & Johnson advances leadership in rheumatic disease innovation With 43 abstracts at ACR 2024",
      "id": 131211870,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SPRING HOUSE - Johnson & Johnson announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology 2024...",
      "url": "https://finnhub.io/api/news?id=a093b1cd9c3d78ac452d743a7ef305fb962dfd4c54f17bc67398c69d7da25b2d"
    }
  }
]